Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
SoniVie announces advancements in its renal denervation program: REDUCED-1 pilot…
Dr. James Zidar (University of North Carolina, NC) presented the 3-month primary efficacy data from the REDUCED-1 Pilot study (N=40 patients, 25 in US and 15 in Israel): an average -12.0 mmHg reduction in daytime ambulatory systolic blood pressure (ASBP) comparing baseline to 3-month was obtained, with 78.4% of patients being responders (≥5mm reduction in daytime ASBP). The responder ASBP 3-month average reduction was -16.2mmHg. No device related adverse events were reported in the 1-month…
PR Newswire
24/07/2024
Tiziana Life Sciences Granted FDA Fast Track Designation
The Fast Track designation is a significant milestone for Tiziana Life Sciences, providing an expedited review process and increased interaction with the FDA. This designation is intended to facilitate the development of and expedite the review of drugs that treat serious conditions and fill an unmet medical need. Only four Fast Track designations have been granted in 2024 by FDA's Center for Drug Evaluation and Research as of March 31, 2024."We are thrilled to receive Fast Track...
Nasdaq GlobeNewswire
24/07/2024
Alkermes plc Reports Second Quarter 2024 Financial Results
— GAAP Net Income from Continuing Operations of $94.7 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.55 — — GAAP Net Income from Continuing Operations of$94.7 Millionand Diluted GAAP Earnings per Share from Continuing Operations of$0.55— — Company Reiterates 2024 Financial Expectations — DUBLIN,July 24, 2024/PRNewswire/ --Alkermes plc(Nasdaq: ALKS) today reported financial results for the second quarter of 2024. "Our second...
PR Newswire
24/07/2024
Tilray Medical Granted Approval to Introduce Third Medical Cannabis Product in…
Tilray's Solução Oral THC10:CBD10 Medical Cannabis Extract is Now Approved for Medical Use in Portugal Tilray Solução Oral THC10:CBD10.Denise Faltischek, Chief Strategy Officer and Head of International at Tilray Brands, Inc., said, "We are proud to have received approval for our Tilray Solução Oral THC10:CBD10 product and expanding our medical cannabis offerings for patients in Portugal. This is a significant step towards meeting the critical needs of patient care and providing...
Nasdaq GlobeNewswire
24/07/2024
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial…
Conference Call & WebcastDate: Thursday, August 1, 2024Time: 4:30 p.m. ETDial In – North American Toll-Free: (800) 836-8184Dial In – International: (646) 357-8785RapidConnect: to join the conference call without operator assistance, please click hereConference ID (if needed): 34386Webcast: please click here Conference Call & WebcastDate :Thursday, August 1, 2024 Time :4:30 p.m. ET Dial In – North American Toll-Free : (800) 836-8184Dial In – International : (646) 357-8785...
PR Newswire
24/07/2024
ADME Toxicology Testing Market Worth 7.12 Billion 2031- Reveals by InsightAce…
ADME is generally applied to investigate the impact of chemicals on human health. Chemicals can be absorbed, distributed, metabolized, or removed in biological systems in this manner. Excretion is a method of eliminating some substances, but not all of them. By considering every pathway a chemical takes as it enters, passes through, and exits the body, human can determine its toxicity. ADME is a crucial term in cellular biology and biochemistry that defines the possible effects that a substance…
PR Newswire
24/07/2024
Pediatric Cardiology Market to Reach US$ 6.5 Billion by 2034, Fueled by Rising…
The increase in the prevalence of congenital heart disorders (CHD) is driving the pediatric cardiology devices market. It is estimated that about one-third of babies born with CHD require some form of intervention early in life, with the majority needing open-heart surgery. The increase in the prevalence of congenital heart disorders (CHD) is driving the pediatric cardiology devices market. It is estimated that about one-third of babies born with CHD require some form of intervention early in...
PR Newswire
24/07/2024
Rapid Growth Forecasted for Micropump Market, projected to Reach US$ 12.4…
Innovations in micropump technologies, including the development of more efficient, reliable, and cost-effective pumps, are contributing to market growth. Significant investments in research and development by key market players and academic institutions are leading to new applications and improved performance of micropumps. Innovations in micropump technologies, including the development of more efficient, reliable, and cost-effective pumps, are contributing to market growth. Significant...
PR Newswire
24/07/2024
deCODE genetics: Variants in the genome affect DNA methylation
The research was published today in the scientific journal Nature Genetics under the title: The correlation between CpG methylation and gene expression is driven by sequence variants. The research was published today in the scientific journalNature Geneticsunder the title: The correlation between CpG methylation and gene expression is driven by sequence variants. Nanopore sequencing is a new technology developed by ONT (Oxford Nanopore Technology), that enables us to analyze DNA...
PR Newswire
24/07/2024
OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in…
OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative ColitisLusvertikimab demonstrates significant efficacy during the 10 week-induction phase of treatment, in the randomized double-blind CotiKis phase 2 study Favorable safety and tolerability profile in the whole patient population across the two doses tested and during the open label phase of treatment First anti-IL7R mAb positive efficacy study...
Nasdaq GlobeNewswire
24/07/2024
2024 Surge in Demand for Trending Collectibles: Collectibles Industry Valued at…
"The growing online marketplace has significantly broadened access to global audience, thereby enhancing the visibility and transactional volume of collectibles. Owing to digitalization leading auction houses are increasingly hosting virtual auctions, which attract a global collector base and drive higher participation rates. Technologies such as blockchain and NFTs are revolutionizing the market by providing digital proof of ownership and authenticity, thereby increasing trust and value in…
PR Newswire
24/07/2024
Aragen Life Sciences Ltd. receives the 2024 Global Customer Value Leadership…
The company provides highly customized services tailored to meet client requirements and leverages cutting-edge technologies, such as artificial intelligence and machine learning, to drive its discovery and development projects to commercialization. The company provides highly customized services tailored to meet client requirements and leverages cutting-edge technologies, such as artificial intelligence and machine learning, to drive its discovery and development projects to…
PR Newswire
24/07/2024
BIOVAXYS ANNOUNCES PLANNED PRIVATE PLACEMENT AND DEBT SETTLEMENT
The Company intends to use the net proceeds of the Private Placement for general working capital purposes including, enabling the Company to fund and advance its business plans in regard to its successful recent acquisition of the entire portfolio of discovery, preclinical and clinical development stage assets in oncology, infectious disease, antigen desensitization, and other immunological fields based on the DPX™ immune educating platform technology, developed by the former Canadian…
PR Newswire
23/07/2024
SKF announces changes to Group Management
A recruitment process to identify a successor has been initiated. A recruitment process to identify a successor has been initiated. Aktiebolaget SKF (publ) CONTACT: For further information, please contact:PRESS: Carl Bjernstam, Head of Media Relations tel: 46 31-337 2517; mobile: 46 722-201 893; e-mail:carl.bjernstam@skf.com INVESTOR RELATIONS: Sophie Arnius, Head of Investor Relations tel: 46 31-337 8072; mobile: 46 705-908 072;sophie.arnius@skf.com This...
PR Newswire
23/07/2024
IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2024
Aggregated presentation by day and by market Purchases of own shares from July 15th to 19th, 2024 Name of the IssuerIdentity code of the IssuerDay of the transactionIdentity code of the financial instrumentTotal daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1115/07/2024FR00102591504 700111,6159XPARIPSEN...
Nasdaq GlobeNewswire
23/07/2024
Global Cardiovascular Health Supplements Market worth $16.06 billion by 2030…
Market Dynamics: Market Dynamics : The Global Cardiovascular Health Supplements Market is primarily driven by the rising prevalence of cardiovascular diseases globally. According to the World Health Organization, cardiovascular diseases are the number 1 cause of death globally, taking an estimated 17.9 million lives each year. Risk factors such as obesity, physical inactivity and increasing stress levels have contributed to the increasing incidence of cardiovascular diseases. Moreover,...
PR Newswire
23/07/2024
Disposable Medical Sensors Market Size to be Worth USD 25.4 billion by 2034…
The disposable medical sensors market is experiencing robust growth, driven primarily by the increasing prevalence of chronic diseases and the need for advanced diagnostic and therapeutic tools. Chronic conditions such as diabetes, cardiovascular diseases, and respiratory disorders necessitate continuous monitoring, thereby boosting the demand for disposable sensors. The disposable medical sensors market is experiencing robust growth, driven primarily by the increasing prevalence of chronic...
PR Newswire
23/07/2024
Molecular Diagnostics Market worth $32.7 billion by 2029 driven by Increasing…
Browse in-depth TOC on "Molecular Diagnostics Market"546 - Tables55 - Figures453 - Pages Browse in-depth TOC on "Molecular Diagnostics Market" 546 - Tables 55 - Figures 453 - Pages DANAHER (US) : Leader in Molecular Diagnostics In 2023, Danaher emerged as the top player in the molecular diagnostics market. The company's established presence within the US provides a strong foundation for expansion into emerging economies, fostering a broader global footprint. Danaher also...
PR Newswire
23/07/2024
Cleanroom Technology Market worth USD 7.28 billion in 2030 - Exclusive Report by…
Get your Sample PDF: https://www.maximizemarketresearch.com/request-sample/28733/ Get your Sample PDF:https://www.maximizemarketresearch.com/request-sample/28733/ Segment Overview MMR has segmented the market based on By Type By Construction By End user Explore Comprehensive Insights Into The Global Cleanroom Technologies Market With A Detailed Sample Report:https://www.maximizemarketresearch.com/request-sample/28733/ Detailed segmentation values...
PR Newswire
23/07/2024
Sleep Apnea Devices Market worth $9.3 billion by 2029 driven by Rising…
Browse in-depth TOC on "Sleep Apnea Devices Market" Browse in-depth TOC on "Sleep Apnea Devices Market" 483 - Table 50 - Figures 366 - Pages RESMED (US): Market Leader in Sleep Apnea Devices ResMed (US) led the sleep apnea devices market in 2023, renowned for its innovative and advanced therapeutic and diagnostic devices. The company's focus on healthcare technology expertise enables it to produce accurate and efficient sleep apnea devices, securing a significant market...
PR Newswire
23/07/2024
Platelet-derived Growth Factors (PDGFs) Market to Reach US$ 478 Million by 2034…
The platelet-derived growth factors market has experienced notable growth over the past few decades, driven by advancements in biotechnology and increased research in regenerative medicine. Treatments for genetic disorders, tissue regeneration techniques, and organ replacements are just some of the areas where RM and gene therapy are already helping to shift healthcare in developed countries like U.S. from symptomatic to curative treatments that are less costly in the long term. The...
PR Newswire
23/07/2024
ViewMind Applauded by Frost & Sullivan for Revolutionizing Brain Health…
ViewMind's patented ocular digital phenotyping uses a head-mounted display and sensors to track eye movements in response to visual stimuli. It employs advanced statistical models to analyze data, detecting even minor cognitive alterations or changes in high-level motor function. The generated report provides valuable insights into the patient's cognitive condition, enabling physicians to make informed decisions. This innovative solution combines advanced testing with a user-friendly experience…
PR Newswire
23/07/2024
Emmes Group partners with Miimansa AI to accelerate adoption of Generative AI in…
The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data and enabling text to text transformations such as protocol authoring and medical writing, reducing the time and cost associated with manual data handling and analysis. The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data and enabling text to text transformations such as protocol authoring and medical writing,...
PR Newswire
23/07/2024
Inspire Medical Systems, Inc. Announces Countrywide Reimbursement in France
“We are thrilled to offer our clinically proven treatment option for moderate to severe OSA to patients and physicians in France,” said Tim Herbert, Chairman and Chief Executive Officer of Inspire. “Inspire therapy is backed by a strong body of evidence and years of clinical experience demonstrating the safety and efficacy of our therapy.”Inspire therapy received European Conformity Marking for commercialization in Europe in 2010. Since that time, the company's approach has been to secure...
Nasdaq GlobeNewswire
23/07/2024
Altri Comunicati
